Willingness to pay for complete symptom relief of gastroesophageal reflux disease
- PMID: 12076234
- DOI: 10.1001/archinte.162.12.1361
Willingness to pay for complete symptom relief of gastroesophageal reflux disease
Abstract
Background: Over $6 billion per year is spent on prescription medication for gastroesophageal reflux disease (GERD). This study is an economic analysis of patients' willingness to pay for a prescription medication that offers complete relief of GERD symptoms.
Methods: The study was a cross-sectional, nonrandomized design recruiting patients from 5 clinical sites. A computer-administered discrete-choice questionnaire was used to explore patients' willingness to pay for various attributes (time to relief, amount of relief, side effects, and out-of-pocket cost) associated with GERD treatment. Patients chose between 2 different combinations of attributes by indicating which scenario they preferred. Data were gathered on health status, health-related quality of life, and sociodemographic characteristics.
Results: Two hundred five patients completed the discrete-choice questionnaire with a consistency rate of 99.5%. All attributes were relevant to patient decision making. Respondents were willing to pay up to $182 to obtain complete relief in a short period of time without side effects. Patients with less severe GERD symptoms were willing to pay more to avoid side effects ($58.25 vs $38.43). Older patients were less willing to pay for better relief than younger patients.
Conclusions: Results demonstrate that patients are willing to pay more per month for a medication that provides more complete and faster relief from GERD symptoms. This information can guide clinicians and formulary committees in evaluating optimal treatment for GERD.
Similar articles
-
Assessing the value of symptom relief for patients with gastroesophageal reflux disease treatment: willingness to pay using a discrete choice experiment.Value Health. 2013 Jun;16(4):588-98. doi: 10.1016/j.jval.2013.01.007. Epub 2013 May 3. Value Health. 2013. PMID: 23796293
-
Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.Clin Exp Nephrol. 2016 Feb;20(1):134-42. doi: 10.1007/s10157-015-1130-2. Epub 2015 May 31. Clin Exp Nephrol. 2016. PMID: 26026991
-
Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy.Am J Manag Care. 1999 May;5(5):631-8. Am J Manag Care. 1999. PMID: 10537869
-
Look--but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment.Digestion. 2007;75 Suppl 1:87-100. doi: 10.1159/000101020. Epub 2007 May 4. Digestion. 2007. PMID: 17489037 Review.
-
Treatment of gastroesophageal reflux disease.Pharm World Sci. 2005 Dec;27(6):432-5. doi: 10.1007/s11096-005-4798-7. Pharm World Sci. 2005. PMID: 16341949 Review.
Cited by
-
Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).Patient. 2014;7(4):413-26. doi: 10.1007/s40271-014-0064-1. Patient. 2014. PMID: 24890711 Free PMC article.
-
Factors that influence patient response to requests to change to a unified restrictive formulary.J Gen Intern Med. 2004 Dec;19(12):1212-9. doi: 10.1111/j.1525-1497.2004.30362.x. J Gen Intern Med. 2004. PMID: 15610332 Free PMC article.
-
A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care.Can J Gastroenterol. 2010 Aug;24(8):489-98. doi: 10.1155/2010/379583. Can J Gastroenterol. 2010. PMID: 20711528 Free PMC article.
-
A Discrete Choice Experiment to Elicit Patient Willingness to Pay for Attributes of Treatment-Induced Symptom Relief in Comorbid. Insomnia.Manag Care. 2015 Apr;24(4):42-8. Manag Care. 2015. PMID: 26489177 Free PMC article.
-
Using discrete choice experiments within a cost-benefit analysis framework: some considerations.Pharmacoeconomics. 2006;24(9):855-68. doi: 10.2165/00019053-200624090-00004. Pharmacoeconomics. 2006. PMID: 16942121
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical